Evogene Ltd.

Prior to being named CEO of Evogene in late 2004, Mr. Haviv held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene's spin-off from Compugen. Prior to the spin-off, he served as Director of Finance and Treasurer of Compugen (NASDAQ: CGEN) for four years, during which time the company completed two private placements and an IPO on NASDAQ. Earlier, Mr. Haviv was the CFO of Klei Zemmer. He was also an auditor with a leading accounting firm belonging to a network of the "Big Five". Mr. Haviv holds a B.A. degree in Economics from Tel Aviv University and is a Certified Public Accountant in Israel. More Info

Dr. Karchi is a co-founder of Evogene and served as its CEO from 2002 to 2004. Prior to the spin-off of Evogene from Compugen he was the Co-Head of Compugen's Plant Genomic Division. He has over 15 years experience in the breeding of tomatoes and in molecular genomics research. His scientific achievements include the development of a molecular system for gene discovery and the development of high yielding, high quality greenhouse tomato varieties. Dr. Karchi has lectured widely in the field of plant genomics and has an extensive record of publications and patents. Dr. Karchi holds B.Sc and M.Sc degrees from the Hebrew University of Jerusalem’s Faculty of Agriculture, specializing in gene expression. He holds a Ph.D. from The Weizmann Institute of Science and the Hebrew University of Jerusalem, Israel. More Info

Mr. Oron has a mixed business and scientific background. Prior to joining Evogene, Mr. Oron was CEO of ChondroSite Ltd., a biotechnology company that develops tissue engineered products in the field of orthopedics (2004-2006). Mr. Oron was previously with Glenrock Ltd., a private investment firm in the field of biotechnology and also has over five years of experience in strategic consulting at POC Ltd., a leading Israeli management consulting company, where he served as senior project manager working with leading companies in Israeli industry. Mr. Oron also has academic experience in the study of protein interactions through bioinformatic means. He holds an M.Sc. degree in Biology and a B.Sc. degree in Economics and Chemistry from Tel Aviv University.

Mr. Kacen is responsible for the technology platform at Evogene, which includes 11 units from bioinformatics, information management and IT, through molecular biology, tissue culture and plant transformation as well as the plant growth, seed bank and seed production units. Prior to joining Evogene, Mr. Kacen was a product manager at Nokia Siemens Networks (2008-2009). He has substantial R&D management experience leading lateral software groups with multiple teams of engineers (2004-2008), implementing advanced development procedures and management methods with proven results. Mr. Kacen holds an MBA from Interdisciplinary Center, Herzliya, with a specialization in Finance and a B.Sc in Communication Systems Engineering from Ben-Gurion University.

Dr. Ayal has been with Evogene since 2004. Before her appointment as VP Technology Expansion, from mid 2011 to mid 2012, she served as Program Management VP and led the Project Management group, which supports Evogene's multiple collaborations with its various partners. From 2009 to 2010, she served as Collaboration Manager and from 2004 to 2009, worked as a trait researcher and was responsible for a variety of projects including cotton fiber and a-biotic stress tolerance. Sharon grew up on a farm, and has over 30 years experience working with agricultural traits, starting with hands-on field work. Research during her studies included work with a tomato breeding team from the Faculty of Agriculture during her first degree, pepper breeding as part of her M.Sc, and work on wheat domestication during her Ph.D. Dr. Ayal holds B.Sc and M.Sc degrees from the Hebrew University of Jerusalem's Faculty of Agriculture, specializing in plant genetics. She holds a Ph.D. from The Weizmann Institute of Science, specializing in plant genetics.

Prior to joining Evogene, Mr. Shachar served as a Program Manager at RADiFlow, a RAD group start-up company, where he led multiyear, million dollar projects, including product planning, development, integration with complex systems and operations activities. Prior to that, Mr. Shachar held a Senior Project Manager position with Nokia Siemens Networks (2008-2011), leading large scale, multiple-team and multidisciplinary projects worldwide. He has substantial R&D development and management experience leading software, hardware and testing groups (2000-2008) of various technologies and business ventures to successful quality products. Mr. Shachar holds a B.Sc. in Communication Systems Engineering from Ben-Gurion University in Beer Sheva, Israel.

Martin Gerstel is Chairman of Compugen Ltd., a publicly owned drug and diagnostic discovery company, Keddem Bioscience, a privately owned drug discovery company and Co-Chairman of Itamar Medical, a publicly owned medical device company. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a pharmaceutical company based on advanced drug delivery. In addition, Mr. Gerstel serves as a director of YEDA Technology Transfer, Yissum Technologies and the Foundation for the US National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and to the Board of the Israel-U.S. BiNational Industrial Research and Development (“BIRD”) Foundation. Mr. Gerstel is a graduate of Yale University and the Stanford Graduate School of Business. More Info

Dr. Michael Anghel serves as a member of various boards of major Israeli corporations, including Partner Ltd., Syneron Medical Ltd., ECI Telecom Ltd., and Scopus Ltd. Previously, Dr. Anghel served on the management of the Discount Investment Corporation and as CEO of Discount Capital Markets, the investment banking arm of the Israel Discount Bank. He was actively involved in the founding and management of various technology and communications enterprises including Cellcom and Tevel. Dr. Anghel holds a B.A. (Economics) from the Hebrew University in Jerusalem and an M.B.A. and Ph.D. from Columbia University in New York. More Info

Dr. Adina Makover currently serves as Director of Life Sciences Investments at Proseed VC and is a consultant to private investors. For the past four years, Dr. Makover has been the managing director of Tzina Bio Perspective, a private investment company focusing on biotechnology and medical device ventures. Previously, she held senior management positions in biotech and device companies focusing on drugs, diagnostics and tissue engineering. Holding positions of CEO and board member, R&D, process development and production manager, Dr. Makover was responsible for both the technology and business aspects. Dr. Makover holds a joint PhD degree in life sciences from Columbia University, New York and the Weizmann Institute of Science (Israel) and performed post-doctoral research at the Weizmann Institute of Science. Dr. Makover also holds an MBA degree from Bar-Ilan University. More Info

Mr. Leon Recanati is the founder and CEO of GlenRock Israel, a private equity group. Mr. Recanati was Chairman and CEO of IDB Holding Corporation, one of the largest investment groups in Israel until May 2003. In addition, he served as Chairman of Clal Industries and Investments, Discount Investment Corporation, and Azorim Investment Development and Construction. Mr. Recanati was Chairman of Delek Israel Fuel Corporation and Shufersal until 1997, in addition to several other positions in a variety of operating companies in Israel. Mr. Recanati's personal involvement in organizations and diverse causes has earned him a reputation as one of Israel's outstanding community leaders. He is Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association and Chairman of Tel Aviv University's Development Committee. He is also an active member of the Board of Governors of Tel Aviv University and the Hebrew University of Jerusalem, The Technion Israel Institute of Technology, The Jewish Agency, and Chairman of Tapuah - The Israeli Society for the Advancement of the Information Age. Mr. Recanati received his BA and MBA degrees from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and Tel Aviv University. More Info

Dr. Simcha Sadan has been a faculty member at Tel Aviv University's business school since 1976. He served as the Chairman of the Tel Aviv University Accounting Department (1977-1980) and as an Assistant Professor at New York University (1972-1975). He is a management and business consultant for various companies and an academic consultant for professional courses. Dr. Sadan has held positions of General Manager and Chief Executive Officer of companies, has been a member of boards of directors and a member of governmental and professional committees. Dr. Sadan holds a PhD in Business Administration from the University of California, Berkeley (1972); an MBA in Accounting and Finance (1967) and a BA in Economics and Statistics (1966), both from the Hebrew University in Jerusalem. Dr. Sadan also holds a Bachelor of Laws (LLB) degree from Tel Aviv University (2002). More Info

Dr. Kinneret Savitsky serves as Chief Executive Officer of BioLineRx Ltd., a publicly traded biopharmaceutical development company. From 2004 to 2009, Dr. Savitsky served as the general manager of BioLine Innovations Jerusalem and was responsible for drug development acceleration and pre-clinical activities. Prior to joining BioLineRx, Dr. Savitsky served as the Vice President of Biology at Compugen Ltd. and was responsible for drug discovery and development in the company. Dr. Savitsky holds a Ph.D. from the Tel Aviv University, a B.Sc. in Biology from the Hebrew University of Jerusalem and a Masters degree in Human Genetics from Tel Aviv University. More Info

In 2010, Bayer CropScience and Evogene entered into a multi-year collaboration focused on improving yield, abiotic stress tolerance and nitrogen use efficiency in wheat. This follows an agreement signed in 2009 which focused on improving rice productivity and yield. More Info

In 2006, Biogemma, of the Limagrain Group, and Evogene entered into a multi-year collaboration, focused on improving yield and draught tolerance in corn. More Info

In 2008, Monsanto and Evogene entered into a multi-year collaboration, focused on improving yield, drought tolerance and nitrogen use efficiency in key commercial crops, including corn, soybean, canola and cotton. The collaboration was extended in 2011. This follows an agreement, signed in 2007, to improve nitrogen use efficiency in key crops. More Info

In 2011, Pioneer Hi-Bred, a subsidiary of DuPont, and Evogene entered into a collaboration, focused on improving resistance to soybean rust. In 2007, the companies signed an agreement for improving yield and abiotic stress tolerance for corn and soybean. More Info

In 2009, Syngenta and Evogene entered into a collaboration focused on improving soybean resistance to Nematodes. More Info